Sanofi (SNY)
Your Dashboard
Displaying SNY Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures 0.00
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield 5.09%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share 0.91
- Earnings Per Share Growth -25.41%
- Earnings Per Share TTM 3.23
- Earnings Yield 9.66%
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses 8.833B
- Expenses TTM 38.54B
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 69.38%
- Gross Profit TTM 31.70B
- Income from Cont. Ops Pro
- Interest Expense 0.00
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt 0.00
- Market Cap 89.65B
- Net Income 2.414B
- Net Income TTM 8.558B
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio 10.35
- PE Value Pro
- PEG Ratio 3.611
- PS Value Pro
- Payout Ratio TTM Pro
- Price 33.43
- Price / Book Value
- Price / Sales Ratio 1.904
- Price / Tangible Book Value Pro
- Profit Margin 21.47%
- R&D Expense 1.542B
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth -1.54%
- Revenue Per Share TTM 17.56
- Revenues 11.25B
- Revenues TTM 47.10B
- SG&A Expense 2.588B
- Shareholders Equity
- Shares Outstanding 2.682B
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price 33.43
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these SNY related companies
SNY News
Sanofi's (SNY) Genzyme Reports Statistically Significant Top-Line Data from TOWER
Jun 01, 7:14AM Street Insider
Jun 01, 7:14AM Street Insider
Sanofi's (SNY) Genzyme, Isis Pharma (ISIS) Says FDA Accepts NDA for KYNAMRO
May 29, 9:23AM Street Insider
May 29, 9:23AM Street Insider
Sanofi (SNY), Regeneron (REGN) Report Additional Positive Data from Study 1003 in Patients w/ heFH
May 29, 6:52AM Street Insider
May 29, 6:52AM Street Insider
Amylin (AMLN) Shares Jump as Bids Due Today, Sanofi (SNY), Merck (MRK) Said to Make First-Round Bids
May 25, 2:01PM Street Insider
May 25, 2:01PM Street Insider
Mylan (MYL) Unit Launches Generic Version of Sanofi-Aventis' (SNY) Plavix
May 17, 1:42PM Street Insider
May 17, 1:42PM Street Insider
$SNY why all the call interest today? Todays most active Options Sanofi 99.6% calls wow... http://stks.co/3qwq
about 16 days ago by justfurkids
about 16 days ago by justfurkids
The Drama Continues At $AMLN: Takeover Still Likely. $BMY $LLY $SNY http://stks.co/3prL
about 17 days ago by abubnic
about 17 days ago by abubnic
5 Top International Dividend Stocks http://stks.co/3kyJ $SNY $CRH $ABB $SID $CS
about 23 days ago by myplaniq
about 23 days ago by myplaniq
$SNY - Closed out at the Initial Stop of $35.62 - http://stks.co/3kS9
about 23 days ago by TraderFoxxx
about 23 days ago by TraderFoxxx
Sanofi's (SNY) Genzyme Gets EMA, FDA Approval for Second Suite at Irish Plant
May 03, 7:37AM Street Insider
May 03, 7:37AM Street Insider
Emerging market push and Genzyme acquisition paying dividends for $SNY 9.9% sales growth significantly outperforming rivals $GSK and $AZN
about 35 days ago by sld1986
about 35 days ago by sld1986
Call $SNY "Stk revalues due to change in biz mix, geo. mix, and lack of patent exposure past '12" http://stks.co/3QzB $PFE $MRK $GSK
about 42 days ago by SumZero
about 42 days ago by SumZero
Quick Pitch: Long on $AZN Target Price: $62 http://stks.co/3Jz7 $SNY $NVS "Best downside protection among Pharma large caps"
about 50 days ago by SumZero
about 50 days ago by SumZero
$AAPL 3D camera patent in works. Who will get the nod as supplier? Either/or/both? $OVTI $SNY >> http://stks.co/3CBy
about 60 days ago by IncrementalWealth
about 60 days ago by IncrementalWealth
Trade Signal-New $SNY -BTO @ 38.08 Limit w/35.62 Stop on the Wkly Chart w/.5N @ Risk http://chart.ly/pygmwen
about 81 days ago by TraderFoxxx
about 81 days ago by TraderFoxxx
News related to $SNY, currently +0.1% since open: 'FDA links once-promising pain drugs to bone decay' http://stks.co/2jWz
about 85 days ago by TradeBot
about 85 days ago by TradeBot
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SNY | 33.43 | -0.60 | -1.76% | 91.26B |
| SNX | 32.83 | -0.52 | -1.56% | 1.236B |
| SNV | 1.71 | -0.20 | -10.47% | 1.513B |
| SNTS | 6.675 | +0.01 | +0.23% | 407.86M |
| SNTA | 5.11 | +0.30 | +6.24% | 277.20M |
| SNT | 0.245 | +0.01 | +6.52% | 21.13M |
| SGU | 3.93 | -0.02 | -0.51% | 242.14M |
| SGRP | 1.24 | +0.00 | +0.00% | 24.92M |
| SGOL | 160.51 | +5.92 | +3.83% | |
| SGNT | 15.98 | +0.03 | +0.19% | 444.69M |
